Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Nephrology
•
General Infectious Disease
How do you approach the use of Paxlovid in patients with COVID-19 and CKD Stage 4?
CKD Stage 4: eGFR between 15 and 29 mL/min/1.73 m²
Nieves MC, et al., PMID 40204015
Related Questions
Would you avoid using cephalosporins in a patient with a history of cephalosporin neurotoxicity in the setting of CKD?
Do you routinely continue dual antibiotic coverage or de-escalate to monotherapy based on peritoneal fluid culture sensitivities in patients with relapsing pseudomonas aeruginosa peritoneal dialysis peritonitis after peritoneal catheter removal?
In light of recent measles outbreaks in the US, would you recommend an MMR booster for an immunocompetent patients born before 1957?
What duration of antibiotic therapy do you use for a loculated parapneumonic effusion that does not meet criteria for empyema?
Do you recommend treatment of male partners for patients with recurrent bacterial vaginosis?
Do you routinely recommend IV systemic antibiotic therapy in additional to intravitreal antibiotic therapy for exogenous bacterial endophthalmitis?
How would you manage persistent Norovirus diarrheal infections in a kidney transplant patient that are not responding to a decrease in the patient’s maintenance immunosuppressive regimen?
Do you routinely transition to PO antibiotics for patients with native joint septic arthritis whom have undergone washout and the organism is not s. aureus?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
What role could emerging technologies, such as antimicrobial coatings or biofilm-disrupting agents, play in reducing the incidence of CIED infections?
